HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Giovanni Battista Luciani Alessandro Mazzucco Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luciani, G. B. Articles by Mazzucco, A. Search for Related Content PubMed PubMed Citation Articles by Luciani, G. B. Articles by Mazzucco, A.

J Thorac Cardiovasc Surg 1998;115:1287-1291
© 1998 Mosby, Inc.

SURGERY FOR ACQUIRED HEART DISEASE

Midterm results after aortic valve replacement with freehand stentless xenografts: a comparison of three prostheses

Read at the Twenty-third Annual Meeting of The Western Thoracic Surgical Association, Napa, Calif., June 25-28, 1997.

Received for publication July 8, 1997. Revisions requested Oct. 10, 1997; revisions received Dec. 1, 1997. Accepted for publication Dec. 30, 1997. Address for reprints: Giovanni Battista Luciani, MD, Division of Cardiac Surgery, University of Verona, O. C. M. Piazzale Stefani 1, Verona, 37126, Italy

Abstract

Objective: The ideal substitute for the diseased aortic valve is yet to be found. For the assessment and comparison of the midterm results after aortic valve replacement with three different types of freehand stentless xenografts, all patients who underwent the operation between October 1992 and April 1997 were reviewed.
Methods: Of 231 patients undergoing aortic valve replacement, 106 patients (group 1) were given the Biocor PSB (Biocor Industria e Pesquisa Ltda, Belo Horizonte, MG, Brazil); 76 patients (group 2) were given the Toronto SPV (St. Jude Medical, Inc., St. Paul, Minn.), and 49 patients (group 3) were given the O'Brien-Angell valve (Bravo Cardiovascular model 300, Cryolife, Inc., Marietta, Ga.). The first two xenografts require inflow and outflow suturelines; the third xenograft needs a single-sutureline implantation. Mean age (70 ± 6 years; 70 ± 7 years; 72 ± 9 years; p = 0.6), prevalence of male sex (56 patients, 53%; 37 patients, 49%; 22 patients, 45%; p = 0.7), of aortic stenosis (72 patients, 68%; 54 patients, 71%; 37 patients, 73%; p = 0.6), and need for associated procedures (51 patients, 48%; 30 patients, 40%; 21 patients, 43%; p = 0.1) were comparable among groups. Mean aortic crossclamp time was shorter in group 3 (96 ± 24 minutes; 100  ± 23 minutes; 88 ± 25 minutes; p = 0.01).
Results: Early deaths were 3 of 106 (3%) in group 1, 2 of 76 (3%) in group 2, and 2 of 49 (4%) in group 3. Follow-up of survivors ranged from 1 to 54 months (mean 32 ± 13 months). Survival at 4 years was 90% ± 3% in group 1, 95% ± 3% in group 2, 85% ± 8% in group 3 (p = 0.3). At 4 years, freedom from valve-related events was 95% ± 6%, 100%, 70% ± 8% (p = 0.004), while freedom from valve deterioration was 99% ± 1%, 100%, 73% ± 8% (p = 0.001), in group 1, 2, and 3, respectively (p = 0.001). At follow-up, reintervention on the xenograft was necessary in one patient (endocarditis) in group 1, none in group 2, and six in group 3 (technical cause, group 3; valve tear, group 2; pannus, group 1). Regression analysis showed O'Brien-Angell type of xenograft to be predictive of valve-related events (p = 0.02), valve deterioration (p = 0.001), and reoperation (p = 0.001) during follow-up.
Conclusions: Midterm survival after stentless aortic valve replacement is good with all three xenografts. Freedom from valve-related events, valve deterioration, and reoperation are excellent with the Biocor PSB or the Toronto SPV stentless valves but less satisfactory with the O'Brien-Angell valve.

This article has been cited by other articles:

				D. Pavoni, L. P. Badano, F. Ius, E. Mazzaro, R. Frassani, S. Gelsomino, and U. Livi Limited Long-Term Durability of the Cryolife O'Brien Stentless Porcine Xenograft Valve Circulation, September 11, 2007; 116(11_suppl): I-307 - I-313. [Abstract] [Full Text] [PDF]

				I. Martinovic, I. Farah, M. Everlien, S. Lindemann, I. Knez, T. Wittlinger, H. Greve, and P. Vogt Eight-year results after aortic valve replacement with the CryoLife-O'Brien Stentless Aortic Porcine Bioprosthesis J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 777 - 777. [Abstract] [Full Text] [PDF]

				G. Polvani, F. Barili, L. Dainese, M. Muratori, M. Porqueddu, A. Sala, and P. Biglioli Long-Term Results After Aortic Valve Replacement With the Bravo 400 Stentless Xenograft Ann. Thorac. Surg., August 1, 2005; 80(2): 495 - 501. [Abstract] [Full Text] [PDF]

				I. Martinovic, M. Everlien, I. Farah, T. Wittlinger, I. Knez, H. Greve, and P. Vogt Midterm Results After Aortic Valve Replacement With a Stentless Bioprosthesis Aortic Valve Ann. Thorac. Surg., July 1, 2005; 80(1): 198 - 203. [Abstract] [Full Text] [PDF]

				D. B. Doty and J. R. Doty Stentless Aortic Valve Replacement: Bioprostheses Card. Surg. Adult, January 1, 2003; 2(2003): 889 - 898. [Full Text]

				G. B. Luciani, F. Santini, S. Auriemma, L. Barozzi, P. Bertolini, and A. Mazzucco Long-term results after aortic valve replacement with the Biocor PSB stentless xenograft in the elderly Ann. Thorac. Surg., May 1, 2001; 71 (2007): S306 - S310. [Abstract] [Full Text] [PDF]